<DOC>
	<DOCNO>NCT00433420</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , epirubicin , cyclophosphamide , paclitaxel , fluorouracil , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . Colony-stimulating factor , pegfilgrastim , may increase number immune cell find bone marrow peripheral blood may help immune system recover side effect chemotherapy . Giving combination chemotherapy pegfilgrastim surgery may kill tumor cell remain surgery . It yet know whether combination chemotherapy effective without fluorouracil and/or pegfilgrastim treat breast cancer . PURPOSE : This randomized phase III trial study combination chemotherapy compare well work give without fluorouracil and/or pegfilgrastim treat woman node-positive breast cancer .</brief_summary>
	<brief_title>Combination Chemotherapy With Without Fluorouracil and/or Pegfilgrastim Treating Women With Node-Positive Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare efficacy adjuvant therapy comprise epirubicin hydrochloride , cyclophosphamide , paclitaxel v without fluorouracil and/or pegfilgrastim woman node-positive breast cancer . Secondary - Compare overall survival patient treat regimen . - Compare safety regimens patient . OUTLINE : This randomize , multicenter study . Patients randomize 1 4 treatment arm . - Arm I : Patients receive epirubicin hydrochloride IV cyclophosphamide IV day 1 . Treatment repeat every 3 week 4 course . Patients receive paclitaxel IV 3 hour day 1 . Treatment paclitaxel repeat every 3 week 4 course . - Arm II : Patients receive fluorouracil IV , epirubicin hydrochloride IV , cyclophosphamide IV day 1 . Treatment repeat every 3 week 4 course . Patients receive paclitaxel arm I . - Arm III : Patients receive epirubicin hydrochloride IV cyclophosphamide IV day 1 pegfilgrastim subcutaneously ( SC ) day 4 . Treatment repeat every 2 week 4 course . Patients receive paclitaxel IV 3 hour day 1 pegfilgrastim subcutaneously ( SC ) day 4 . Treatment paclitaxel pegfilgrastim repeat every 2 week 4 course . - Arm IV : Patients receive fluorouracil IV , epirubicin hydrochloride IV , cyclophosphamide IV day 1 pegfilgrastim SC day 4 . Treatment repeat every 2 week 4 course . Patients receive paclitaxel pegfilgrastim arm III . In arm , treatment continue absence disease progression unacceptable toxicity . After completion chemotherapy without pegfilgrastim , patient may undergo external-beam radiation therapy discretion treat center . Patients positive estrogen and/or progesterone receptor tumor receive tamoxifen 5 year . After completion study treatment , patient follow periodically 5 year annually thereafter . PROJECTED ACCRUAL : A total 2,000 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm primary breast cancer No histology carcinoma Nodepositive disease Must least 1 involved axillary node internal mammary node Previously resect disease Has undergone radical surgery ( i.e. , mastectomy conservative surgery ) axillary node dissection within past 7 week No inflammatory carcinoma No prior concurrent ipsilateral contralateral invasive breast carcinoma No metastatic disease , include metastasis ipsilateral supraclavicular lymph node Hormone receptor status specify PATIENT CHARACTERISTICS : Female Menopausal status specify ECOG performance status 01 Absolute neutrophil count ≥ 1,500/mm³ WBC ≥ 4,000/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 9 g/dL Bilirubin ≤ 1.5 time upper limit normal ( ULN ) Creatinine ≤ 1.5 time ULN AST ALT ≤ 2.5 time ULN Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No chronic liver renal disease No serious medical illness require medication No malignancy except adequately treat , conebiopsied situ carcinoma cervix basal cell squamous cell carcinoma skin No symptomatic peripheral neuropathy &gt; grade 2 No hypersensitivity study drug components No recent myocardial infarction , congestive heart failure , serious arrhythmia PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior chemotherapy No prior cytotoxic regimens No prior radiation therapy , except intraoperative radiation therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
</DOC>